Skip to main content

Advertisement

SpringerLink
Log in

Predictive value of FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas: a retrospective study

  • Original Article
  • Published:
Clinical Oral Investigations Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Objectives

The aim of this study was to investigate the predictive value of the biomarkers FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas.

Material and methods

Immunohistochemical staining of FHIT, p27, and pERK1/ERK2 of 265 patients with salivary gland carcinomas was conducted, and associations with clinico-histopathological data, overall survival, and disease-specific survival were examined.

Results

Expression of FHIT (quick score 98.7 vs. 206.4) and p27 (QS 187.3 vs. 244.8) was significantly lower in carcinomas compared to non-tumor control tissue. Loss of FHIT frequently occurred in ACC (55.2%), SDC (68.2%), and SCC (100%). In the totality of tumors, loss of FHIT expression was found in 46.7% (106/227) and was significantly associated with advanced T stage and UICC stage, high-grade histology, loss of p27, PI3K, and survivin. FHIT positivity went along with significantly better overall and disease-specific survival. Negativity of p27 occurred in 28.7% (70/244) of tumors, particularly in SDC (54.4%) and SCC (50%). In the totality of tumors, p27 was associated with advanced patient age, high-grade histology, PI3K, survivin as well as better overall and disease-specific survival (p < 0.05). Positive pERK1/ERK2 expression correlated with positive survivin expression but did not affect overall survival in the totality of tumors. In mucoepidermoid carcinomas, pERK1/ERK2 expression was associated with low-grade malignancy, positive nuclear survivin, and better disease-specific survival.

Conclusions

Loss of FHIT and p27 characterizes aggressive tumor growth and unfavorable prognosis in salivary gland cancer.

Clinical relevance

The results may help to stratify patient-specific therapies according to individual tumor characteristics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Speight P, Barrett A (2002) Salivary gland tumours. Oral Dis 8:229–240

    Article  Google Scholar 

  2. El-Naggar AK (2017) What is new in the World Health Organization 2017 histopathology classification? Curr Treat Options in Oncol 18:43. https://doi.org/10.1007/s11864-017-0469-x

    Article  Google Scholar 

  3. Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM (2002) FHIT: from gene discovery to cancer treatment and prevention. Lancet Oncol 3:748–754. https://doi.org/10.1016/s1470-2045(02)00931-2

    Article  PubMed  Google Scholar 

  4. Dincer N, Tezel GG, Sungur A, Himmetoglu C, Huebner K, Guler G (2010) Study of FHIT and WWOX expression in mucoepidermoid carcinoma and adenoid cystic carcinoma of salivary gland. Oral Oncol 46:195–199. https://doi.org/10.1016/j.oraloncology.2009.12.003

    Article  PubMed  Google Scholar 

  5. Semba S, Trapasso F, Fabbri M, McCorkell KA, Volinia S, Druck T, Iliopoulos D, Pekarsky Y, Ishii H, Garrison PN, Barnes LD, Croce CM, Huebner K (2006) Fhit modulation of the Akt-survivin pathway in lung cancer cells: Fhit-tyrosine 114 (Y114) is essential. Oncogene 25:2860–2872. https://doi.org/10.1038/sj.onc.1209323

    Article  PubMed  Google Scholar 

  6. Okabe M, Inagaki H, Murase T, Inoue M, Nagai N, Eimoto T (2001) Prognostic significance of p27 and Ki-67 expression in mucoepidermoid carcinoma of the intraoral minor salivary gland. Mod Pathol 14:1008–1014

    Article  Google Scholar 

  7. Chu IM, Hengst L, Slingerland JM (2008) The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 8:253–267. https://doi.org/10.1038/nrc2347

    Article  PubMed  Google Scholar 

  8. Ben-Izhak O, Akrish S, Gan S, Nagler RM (2009) p27 and salivary cancer. Cancer Immunol Immunother 58:469–473. https://doi.org/10.1007/s00262-008-0547-9

    Article  PubMed  Google Scholar 

  9. Handra-Luca A, Ruhin B, Lesty C, Fouret P (2006) P27, SKP2, and extra-cellular signal-related kinase signalling in human salivary gland mucoepidermoid carcinoma. Oral Oncol 42:1005–1010. https://doi.org/10.1016/j.oraloncology.2005.12.022/c

    Article  PubMed  Google Scholar 

  10. Donovan JC, Milic A, Slingerland JM (2001) Constitutive MEK/MAPK activation leads to p27(Kip1) deregulation and antiestrogen resistance in human breast cancer cells. J Biol Chem 276:40888–40895. https://doi.org/10.1074/jbc.M106448200

    Article  PubMed  Google Scholar 

  11. Burotto M, Chiou VL, Lee JM, Kohn EC (2014) The MAPK pathway across different malignancies: a new perspective. Cancer 120:3446–3456. https://doi.org/10.1002/cncr.28864

    Article  PubMed  PubMed Central  Google Scholar 

  12. Barnes L, Eveson J, Reichart P, Sidransky D (2005) Pathology and genetics of head and neck tumours. World Health Organization classification of Tumours. IARC, Lyon

    Google Scholar 

  13. Ettl T, Schwarz-Furlan S, Haubner F, Müller S, Zenk J, Gosau M, Reichert TE, Zeitler K (2012) The PI3K/AKT/mTOR signalling pathway is active in salivary gland cancer and implies different functions and prognoses depending on cell localisation. Oral Oncol 48:822–830

    Article  Google Scholar 

  14. Ettl T, Stiegler C, Zeitler K, Agaimy A, Zenk J, Reichert TE, Gosau M, Kühnel T, Brockhoff G, Schwarz S (2012) EGFR, HER2, survivin, and loss of pSTAT3 characterize high-grade malignancy in salivary gland cancer with impact on prognosis. Hum Pathol 43:921–931

    Article  Google Scholar 

  15. Milanes-Yearsley M, Hammond ME, Pajak TF, Cooper JS, Chang C, Griffin T, Nelson D, Laramore G, Pilepich M (2002) Tissue micro-array: a cost and time-effective method for correlative studies by regional and national cancer study groups. Mod Pathol 15:1366–1373. https://doi.org/10.1097/01.MP.0000036345.18944.22

    Article  PubMed  Google Scholar 

  16. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, Rougier P, Lievre A, Landi B, Boige V, Ducreux M, Ychou M, Bibeau F, Bouche O, Reid J, Stone S, Penault-Llorca F (2009) Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27:5924–5930. https://doi.org/10.1200/JCO.2008.21.6796

    Article  PubMed  Google Scholar 

  17. Cao J, Li W, Xie J, Du H, Tang W, Wang H, Chen X, Xiao W, Li Y (2006) Down-regulation of FHIT inhibits apoptosis of colorectal cancer: mechanism and clinical implication. Surg Oncol 15:223–233. https://doi.org/10.1016/j.suronc.2007.01.006

    Article  PubMed  Google Scholar 

  18. Woenckhaus M, Merk J, Stoehr R, Schaeper F, Gaumann A, Wiebe K, Hartmann A, Hofstaedter F, Dietmaier W (2008) Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol 39:126–136. https://doi.org/10.1016/j.humpath.2007.05.027

    Article  PubMed  Google Scholar 

  19. Dumon K, Ishii H, Vecchione A, Trapasso F, Baldassarre G, Chakrani F, Druck T, Rosato E, Williams N, Baffa R, During M, Huebner K, Croce C (2001) Fragile histidine triad expression delays tumor development and induces apoptosis in human pancreatic cancer1. Cancer Res 61:4827–4836

    PubMed  Google Scholar 

  20. Huang Q, Liu Z, Xie F, Liu C, Shao F, Zhu CL, Hu S (2014) Fragile histidine triad (FHIT) suppresses proliferation and promotes apoptosis in cholangiocarcinoma cells by blocking PI3K-Akt pathway. ScientificWorldJournal 2014:179698. https://doi.org/10.1155/2014/179698

    Article  PubMed  PubMed Central  Google Scholar 

  21. Li F, Yang J, Ramnath N, Javle MM, Tan D (2005) Nuclear or cytoplasmic expression of survivin: what is the significance? Int J Cancer 114:509–512. https://doi.org/10.1002/ijc.20768

    Article  PubMed  PubMed Central  Google Scholar 

  22. Zhao P, Meng Q, Liu LZ, You YP, Liu N, Jiang BH (2010) Regulation of survivin by PI3K/Akt/p70S6K1 pathway. Biochem Biophys Res Commun 395:219–224. https://doi.org/10.1016/j.bbrc.2010.03.165

    Article  PubMed  Google Scholar 

  23. Sarli L, Bottarelli L, Azzoni C, Campanini N, Di Cola G, Barilli AL, Marchesi F, Mazzeo A, Salvemini C, Morari S, Di Mauro D, Donadei E, Necchi F, Roncoroni L, Bordi C (2006) Loss of p27 expression and microsatellite instability in sporadic colorectal cancer. Surg Oncol 15:97–106. https://doi.org/10.1016/j.suronc.2006.09.002

    Article  PubMed  Google Scholar 

  24. Handra-Luca A, Bilal H, Bertrand J-C, Fouret P (2003) Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland Mucoepidermoid carcinoma. Am J Pathol 163:957–967. https://doi.org/10.1016/s0002-9440(10)63455-4

    Article  PubMed  PubMed Central  Google Scholar 

  25. Deschenes-Simard X, Kottakis F, Meloche S, Ferbeyre G (2014) ERKs in cancer: friends or foes? Cancer Res 74:412–419. https://doi.org/10.1158/0008-5472.CAN-13-2381

    Article  PubMed  Google Scholar 

  26. Milde-Langosch K, Bamberger AM, Rieck G, Grund D, Hemminger G, Muller V, Loning T (2005) Expression and prognostic relevance of activated extracellular-regulated kinases (ERK1/2) in breast cancer. Br J Cancer 92:2206–2215. https://doi.org/10.1038/sj.bjc.6602655

    Article  PubMed  PubMed Central  Google Scholar 

  27. Lujan B, Hakim S, Moyano S, Nadal A, Caballero M, Diaz A, Valera A, Carrera M, Cardesa A, Alos L (2010) Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands. Br J Cancer 103:510–516. https://doi.org/10.1038/sj.bjc.6605788

    Article  PubMed  PubMed Central  Google Scholar 

  28. Chen X, Duan N, Zhang C, Zhang W (2016) Survivin and tumorigenesis: molecular mechanisms and therapeutic strategies. J Cancer 7:314–323. https://doi.org/10.7150/jca.13332

    Article  PubMed  PubMed Central  Google Scholar 

  29. Ettl T, Baader K, Stiegler C, Muller M, Agaimy A, Zenk J, Kuhnel T, Gosau M, Zeitler K, Schwarz S, Brockhoff G (2012) Loss of PTEN is associated with elevated EGFR and HER2 expression and worse prognosis in salivary gland cancer. Br J Cancer 106:719–726. https://doi.org/10.1038/bjc.2011.605

    Article  PubMed  PubMed Central  Google Scholar 

  30. Ettl T, Schwarz S, Kleinsasser N, Hartmann A, Reichert TE, Driemel O (2008) Overexpression of EGFR and absence of C-KIT expression correlate with poor prognosis in salivary gland carcinomas. Histopathology 53:567–577. https://doi.org/10.1111/j.1365-2559.2008.03159.x

    Article  PubMed  Google Scholar 

  31. Ach T, Zeitler K, Schwarz-Furlan S, Baader K, Agaimy A, Rohrmeier C, Zenk J, Gosau M, Reichert TE, Brockhoff G, Ettl T (2013) Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer. Virchows Arch 462:65–72. https://doi.org/10.1007/s00428-012-1358-0

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We wish to thank Rudolf Jung for his excellent immunohistochemical stainings.

Author information

Authors and Affiliations

  1. Department of Oral and Maxillofacial Surgery, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany

    Mathias Fiedler, Patty Renner, Torsten E. Reichert & Tobias Ettl

  2. Neckarstr.16, 95445, Bayreuth, Germany

    Jürgen Schubert

  3. Department of Pathology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany

    Florian Weber

  4. Institute of Pathology, University Hospital of Erlangen, Krankenhausstraße 8/10, 91054, Erlangen, Germany

    Arndt Hartmann

  5. Department of Otorhinolaryngology and Head and Neck Surgery, University of Erlangen-Nuremberg, Waldstraße 1, 91054, Erlangen, Germany

    Heinrich Iro

  6. Department of Otorhinolaryngology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany

    Veronika Vielsmeier & Christopher Bohr

  7. Center of Tumor Registry, University of Regensburg, Am BioPark 9, 93053, Regensburg, Germany

    Michael Gerken

Authors
  1. Mathias Fiedler
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patty Renner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jürgen Schubert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Florian Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Arndt Hartmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Heinrich Iro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Veronika Vielsmeier
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christopher Bohr
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michael Gerken
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Torsten E. Reichert
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tobias Ettl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tobias Ettl.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study has been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Informed consent

For this type of study, formal consent is not required.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fiedler, M., Renner, P., Schubert, J. et al. Predictive value of FHIT, p27, and pERK1/ERK2 in salivary gland carcinomas: a retrospective study. Clin Oral Invest 23, 3801–3809 (2019). https://doi.org/10.1007/s00784-019-02809-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00784-019-02809-z

Keywords

Search

Navigation